8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 Current Report


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of report (date of earliest event reported): October 8, 2008

                               Balchem Corporation
             (Exact name of registrant as specified in its charter)

Maryland                                   1-13648           13-257-8432
(State or other jurisdiction of   (Commission File Number)   (IRS Employer
incorporation)                                               Identification No.)

                       P.O. Box 600, New Hampton, NY 10958
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (845) 326-5600

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



Item 7.01   Regulation FD Disclosure.

         On October 8, 2008, Balchem Corporation (the (Company") issued a press
release announcing the launch of its new rumen-protected lysine product. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.

         The information in this Form 8-K (including Exhibit 99.1) shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934
(the "Exchange Act") or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item 9.01  Financial Statements and Exhibits.

(c)  Exhibits

Exhibit 99.1         Press Release of Balchem Corporation dated October 8, 2008.





                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                              BALCHEM CORPORATION


                                              By:/s/ Dino A. Rossi
                                              ----------------------------------
                                              Dino A. Rossi, President &
                                              Chief Executive Officer

Dated: October 9, 2008





                                  Exhibit Index


Exhibit Number       Description
- --------------       -----------


99.1                 Press Release of Balchem Corporation dated October 8, 2008.

EX-99.1

Exhibit 99.1




For Immediate Release
- ---------------------


                                                     For More Information:
                                                     Dr. Dana E. Putnam
                                                     Balchem
                                                     845-326-5693 Phone
                                                     dputnam@balchem.com
                                                     www.balchem.com



                               Balchem Introduces
                             Rumen-Protected Lysine

New Hampton, New York. October 8, 2008. Balchem Corporation (NASDAQ: BCPC)
announced that the first proven rumen-protected lysine for use in dairy rations
was introduced by the Animal Nutrition and Health Division of Balchem at the
World Dairy Expo in Madison, Wisconsin.

         "AminoShure(TM)-L gives nutritionists and dairy producers a long
awaited source of rumen-protected lysine," says Dr. Dana Putnam, Vice President
and General Manager of Balchem's Animal Nutrition and Health Division. "It
provides the industry with a precise and consistent source of lysine that can be
used in concert with or replacement of typical feed sources of lysine which are
often inadequate or inconsistent sources of lysine.

         "AminoShure(TM)-L permits ration formulations that more closely
approximate an animal's lysine requirements without the excesses of crude
protein that typically accompany lysine in conventional feed ingredients. This
opens the door to higher milk production with desired milk component levels and,
equally important, to less nitrogen excreted as waste."

         Research has clearly shown that limitations in lysine supply to a dairy
cow will limit milk component levels and milk production. Cows typically are
unable to synthesize adequate quantities of lysine to fully meet nutritional
requirements and most protein supplements contain insufficient lysine for cows.
Despite years of research and development, the dairy industry has lacked a
practical and consistent tool to effectively meet the lysine demands of cows,
until now.

           Balchem's position as the global leader in nutrient delivery
technology, including over 100 different encapsulated products for animal, human
and industrial markets, uniquely positions it to solve this type of challenge.
AminoShure-L, which is the culmination of an intensive six year research
program, benefiting from Balchem's growing proprietary encapsulation technology,
successfully bypasses the rumen and reaches the small intestine, where it is
readily released and absorbed.

Segment Information

Balchem Corporation consists of three business segments: ARC Specialty Products;
Food, Pharma and Nutrition; and Animal Nutrition and Health. Through ARC
Specialty Products, Balchem provides specialty-packaged chemicals for use in
healthcare and other industries. The Food, Pharma and Nutrition segment provides
proprietary micro encapsulation, granulation and agglomeration solutions to a
variety of applications in the human food, pharmaceutical and nutrition
marketplaces. The Animal Nutrition and Health segment manufactures and supplies
products, including encapsulated ingredients, Keyshure (TM) organic trace
minerals and animal grade choline to numerous animal health markets and certain
derivative products into industrial applications.

Forward Looking Statements

This release contains forward-looking statements, which reflect Balchem's
expectation or belief concerning future events that involve risks and
uncertainties. Balchem can give no assurance that the expectations reflected in
forward looking statements will prove correct and various factors could cause
results to differ materially from Balchem's expectations, including risks and
factors identified in Balchem's annual report on Form 10-K for the year ended
December 31, 2007. Forward-looking statements are qualified in their entirety by
the above cautionary statement. Balchem assumes no duty to update its outlook or
other forward-looking statements as of any future date.